hematological malignancies
Conditions
Interventions
Patients receives a 50-mg dose of micafungin once daily as a 1-hour infusion. This prophylaxis is initiated within 24 hours of the beginning of the transplant-related conditioning regimen. Patients re
5 days after engraftment (defined as an absolute neutrophil count of 500 cells/mm3 after the nadir absolute count).
Sponsors
The Jikei university school of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients undergoing hematopoietic stem cell transplantation (Age 16 > years) Patients do not have received antifungal therapy within 72 hours before adminiatrarion of the first dose of the study drug.
Exclusion criteria
Exclusion criteria: Patients are free of fungal infection at the time of enrollment. Patients have a history of a serious allergy to the study drug. Patients have a serious liver dysfunction. Patients have received micafungin within 7 days before the time of enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end point is treatment success, which is defined as the absence of fungal infection through the prophylaxis therapy of micafungin and as the absence of fungal infection through the end of the 4-week posttreatment period. | — |
Countries
Japan
Outcome results
None listed